7.75
+0.59(+8.24%)
Currency In USD
Previous Close | 7.16 |
Open | 7.19 |
Day High | 7.76 |
Day Low | 7.18 |
52-Week High | 61.9 |
52-Week Low | 4.64 |
Volume | 270,631 |
Average Volume | 172,847 |
Market Cap | 94.84M |
PE | -1.83 |
EPS | -4.24 |
Moving Average 50 Days | 7.74 |
Moving Average 200 Days | 12.36 |
Change | 0.59 |
If you invested $1000 in Corbus Pharmaceuticals Holdings, Inc. (CRBP) 10 years ago, it would be worth $84.7 as of July 03, 2025 at a share price of $7.75. Whereas If you bought $1000 worth of Corbus Pharmaceuticals Holdings, Inc. (CRBP) shares 5 years ago, it would be worth $32.66 as of July 03, 2025 at a share price of $7.75.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
GlobeNewswire Inc.
Jun 30, 2025 12:00 PM GMT
No treatment-related neuropsychiatric events seen to date in SAD portion of Phase 1MAD study on track for completion in Q3 2025 NORWOOD, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage
Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab
GlobeNewswire Inc.
Jun 25, 2025 12:00 PM GMT
Combination cohort initiated following successful review of monotherapy cohortOver 100 participants dosed to-date in monotherapy cohortPriority are Head and Neck Squamous Cell Carcinoma (HNSCC) and cervical cancerData update on schedule for later thi
Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium
GlobeNewswire Inc.
Jun 24, 2025 8:05 PM GMT
NORWOOD, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fire side chat at